Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial statements or performance metrics.
Material Changes
The filing reports an increase in the interest of Dr. M. M. Slaoui in Ordinary shares. This transaction resulted from the re-investment of the dividend paid to shareholders on October 6, 2011. The shares were purchased on October 12, 2011, at a price of 1382 pence per share, adding 303 shares to Dr. Slaoui's holdings.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of a director's share transaction.
Key Facts for Investor Verification
- Director Dr. M. M. Slaoui acquired 303 additional Ordinary shares.
- The acquisition price was 1382 pence per share.
- The transaction occurred on October 12, 2011, via the GlaxoSmithKline Annual Investment Plan.
- The purchase was funded by the re-investment of the dividend paid on October 6, 2011.